Arvinas (ARVN) Shares Outstanding (Weighted Average) (2017 - 2026)
Arvinas (ARVN) recorded quarterly Shares Outstanding (Weighted Average) of $64.0 million in Q1 2026, down 9.73% quarter-over-quarter from $70.9 million in Q4 2025, and down 11.72% on a YoY basis from $72.5 million in Q1 2025.
Arvinas (ARVN) Shares Outstanding (Weighted Average) (2017 - 2026) Analysis & Trends
Arvinas' Shares Outstanding (Weighted Average) history runs 10 years deep, the most recent figure standing at $64.0 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Weighted Average) fell 11.72% year-over-year to $64.0 million; the TTM figure through Mar 2026 stood at $64.0 million (down 11.72% YoY), while the FY2025 annual figure was $70.9 million, down 1.39% from the prior year.
- Shares Outstanding (Weighted Average) was $64.0 million for Q1 2026 at Arvinas, down from $70.9 million in the prior quarter.
- In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $72.9 million in Q3 2025 to a low of $53.0 million in Q1 2022.
- Historically, Shares Outstanding (Weighted Average) has averaged $62.9 million across 5 years, with a median of $64.0 million in 2026.
- The sharpest annual moves came in 2024 and 2026: Shares Outstanding (Weighted Average) soared 34.64% in 2024, then decreased 11.72% in 2026.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $53.2 million in 2022, then grew by 4.32% to $55.5 million in 2023, then advanced by 29.55% to $71.9 million in 2024, then retreated by 1.39% to $70.9 million in 2025, then dropped by 9.73% to $64.0 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $64.0 million (Q1 2026), $70.9 million (Q4 2025), and $72.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 185,491.37 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 400.00 Bn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 100.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 417.01 Bn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 68.88 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 254.10 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 928.40 Mn |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - | 64.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 64.00 Mn |
| Dec 31, 2025 | 70.90 Mn |
| Sep 30, 2025 | 72.90 Mn |
| Jun 30, 2025 | 72.80 Mn |
| Mar 31, 2025 | 72.50 Mn |
| Dec 31, 2024 | 71.90 Mn |
| Sep 30, 2024 | 72.10 Mn |
| Jun 30, 2024 | 71.90 Mn |
| Mar 31, 2024 | 71.70 Mn |
| Dec 31, 2023 | 55.50 Mn |
| Sep 30, 2023 | 53.60 Mn |
| Jun 30, 2023 | 53.40 Mn |
| Mar 31, 2023 | 53.30 Mn |
| Dec 31, 2022 | 53.20 Mn |
| Sep 30, 2022 | 53.20 Mn |
| Jun 30, 2022 | 53.10 Mn |
| Mar 31, 2022 | 53.00 Mn |
| Dec 31, 2021 | 50.00 Mn |
| Sep 30, 2021 | 49.80 Mn |
| Jun 30, 2021 | 48.70 Mn |